Matt Hoffman

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis pigmentosa, with the phase 3 VISTA study fully enrolled.

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Geographic atrophy management evolves with proactive imaging, personalized therapies, and real-world insights, enhancing patient care and treatment outcomes.

Guest lecturer explores the emerging frontiers in ROP therapy and the evolving ethical, clinical, and technological considerations.

Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments.